Search results
Results from the WOW.Com Content Network
U.S officials last week said they were moving bulk vaccine from CSL Seqirus that closely matches the current virus into finished shots that could provide 4.8 million doses of vaccine. European ...
The funds will allow for pharmaceutical companies CSL Seqirus, Sanofi, and GSK to "fill and finish"-- a process to fill vaccines from bulk storage into ready-to-use vials or pre-filled syringes ...
CSL Limited is an Australian multinational specialty biotechnology company that researches, develops, manufactures, and markets products to treat and prevent serious human medical conditions. CSL's product areas include blood plasma derivatives, vaccines , antivenom , and cell culture reagents used in various medical and genetic research and ...
In May 2024, CSL Seqirus was selected by the US government to supply 4.8 million doses of an H5 vaccine to the National Pre-Pandemic Influenza Vaccine Stockpile program. The vaccine is well matched to the H5N1 strains currently circulating in wild birds and cattle. [19]
In 2014, CSL Limited obtained Novartis' flu vaccine unit, and transferred it to CSL Subsidiary, bioCSL, named Seqirus. [17] The following are list of bioCSL flu vaccine brands: [31] Trivalent. Afluria, also marketed as Enzira, Fluvax, and Nilgrip in various different markets
The U.S. has two vaccines ready that could begin shipping widely within a few weeks if the H5N1 bird flu infecting dairy cows begins spreading more easily to people, federal health officials said ...
Zoonotic influenza vaccine Seqirus is authorized for use in the European Union. [1] It contains a flu strain called A/Astrakhan/3212/2020 (H5N8)-like strain (CBER-RG8A) (clade 2.3.4.4b). [ 1 ] Zoonotic influenza vaccine Seqirus was considered to be the best candidate to provide protection against circulating H5 influenza A strains.
CSL Behring is a biopharmaceutical company, manufacturing plasma-derived and recombinant therapeutic products. [2] The company is a combination of Behringwerke, founded in 1904 in Marburg, Germany by Emil von Behring, and the Commonwealth Serum Laboratories (CSL), established in Australia in 1916 to provide vaccines to the people of Australia, as well as other companies acquired since 2004.